Ro vs Gala Health
Two GLP-1 desks, one scoreboard. We put Ro and Gala Health head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
The verdict
Ro takes this head-to-head.
Ro scores 87 to 86 on our six-factor Brief Score — A heavyweight platform with brand-name access and a polished experience — but it keeps compounded pricing off the record.
That doesn't make Gala Health a bad call — it's best for readers who want a low compounded-tirzepatide starting price in all 50 states but like knowing a brand-name ozempic route exists if they ever switch — and who value a menopause/hrt program alongside the glp-1. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Ro | Gala Health | |
|---|---|---|
| Brief Score | 87/100 (B+) | 86/100 (B) |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | $179/mo |
| Coverage | Multi-state | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Stableprice stable | Stableprice stable |
Ro: Brand-name access and insurance navigation, but compounded pricing stays off the record.
Gala Health: Low compounded-tirz entry unchanged this cycle; the desk pairs it with a brand-name lane most compounding-only shops don't offer.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.